Open AccessAnti-Zo antibodies in Japanese myositis patients detected by a newly developed ELISA
Author(s) -
Yoshinao Muro,
Takako Hashimoto,
Shinyu Izumi,
Mariko OgawaMomohara,
Takuya Takeichi,
Hiroyuki Yamashita,
Hidekata Yasuoka,
Masashi Akiyama
Publication year - 2022
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/q70vmh
Subject(s) - polymyositis , autoantibody , dermatomyositis , medicine , myositis , immunoprecipitation , antibody , myopathy , interstitial lung disease , cohort , blot , recombinant dna , immunology , ctd , connective tissue disease , gastroenterology , pathology , autoimmune disease , lung , biology , genetics , gene , oceanography , geology
The myositis-specific autoantibodies that characterise certain forms of idiopathic inflammatory myopathy (IIM) are useful for diagnosing dermatomyositis (DM) / polymyositis (PM) and predicting its prognosis. The autoantibody to phenylalanyl-tRNA synthetase (anti-Zo) has been identified as a disease marker antibody for anti-synthetase syndrome only in a UK cohort. Here we aim to establish an ELISA for the measurement of anti-Zo and to characterise the clinical features of Japanese patients who have this autoantibody.